Articles

  • 1 week ago | medscape.com | M. Alexander Otto

    Immune checkpoint inhibitors (ICI) are a cornerstone of non-small cell lung cancer (NSCLC) treatment, but it’s not clear whether adding chemotherapy to ICI — a common practice with younger patients with NSCLC — helps older ones. No randomized trial has directly compared stand-alone ICI with chemoimmunotherapy in geriatric patients with NSCLC.

  • 1 week ago | medscape.com | M. Alexander Otto

    The US Food and Drug Administration has approved tafasitamab (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory (r/r) follicular lymphoma (FL). Lenalidomide with rituximab (R2) is already a common, chemotherapy-free option for FL in the first, and especially second, lines. Adding tafasitamab, an anti-CD19 immunotherapy, improved progression-free survival (PFS) from 14.1 to 22.4 months in inMIND, Incyte’s approval trial.

  • 2 weeks ago | medscape.com | M. Alexander Otto

    The FDA has approved a before and after surgery regimen for pembrolizumab to improve outcomes in resectable locally-advanced head and neck squamous cell carcinoma (HNSCC). Specifically, the new approval is for HNSCC tumors that express PD-L1, with pembrolizumab as a single agent in the neoadjuvant setting, followed by radiation plus/minus cisplatin after surgery, and continuing as a single agent for maintenance.

  • 2 weeks ago | medscape.com | M. Alexander Otto

    The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin formulation is meant to be an alternative to the current standard of care for recurrent disease: Transurethral resection of bladder tumor (TURBT). The surgical procedure is usually done under general anesthesia, while Zusduri can be instilled by a catheter in a urologist’s office. Treatment is once a week for 6 weeks.

  • 2 weeks ago | medscape.com | M. Alexander Otto

    The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
161
Tweets
271
DMs Open
Yes
M. Alexander Otto
M. Alexander Otto @MAlexanderOtto
15 Jun 23

important study for oncologists https://t.co/PdlN59TZlo

M. Alexander Otto
M. Alexander Otto @MAlexanderOtto
9 Dec 22

[tweet to keep acct active]

M. Alexander Otto
M. Alexander Otto @MAlexanderOtto
17 Apr 20

Fresh of the press. Indeed, it is a nasty little bug, but things are looking up on Long Island, anyways. Can you imagine 70 people all intubated at once? Like a sci-fi nightmare... @MDEdgeTweets @AmerMedicalAssn @Medscape @ivanoransky @hmkyale https://t.co/qKf5eZAwa8